Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding, Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).

NCT06125808 is registered in ClinicalTrials.gov with Arctic Bioscience as lead sponsor.

NCT NCT06125808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06125808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding, Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).
Lead sponsor
Arctic Bioscience
Phase
Phase 2
Overall status
Completed
Start date
May 25, 2023
Completion date
March 7, 2025
Enrollment
521 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis